Biogen stock fell 4.97% after reporting Phase 2 results for its Alzheimer's drug diranersen, which missed its primary endpoint but showed cognitive benefits and tau biomarker reductions across all doses. The company plans to advance the therapy to registrational development. Separately, Biogen completed its acquisition of Apellis Pharmaceuticals, adding two commercial drugs worth $689 million in 2025 revenue.

Biogen has successfully completed its acquisition of Apellis Pharmaceuticals for $41 per share plus contingent value rights. The deal adds two commercialized products—EMPAVELI and SYFOVRE—which generated $689 million in net product revenue in 2025. The acquisition is expected to be accretive to Biogen's non-GAAP diluted EPS in 2027 and significantly boost the company's growth outlook, particularly in nephrology.

Biogen shares rose 1.06% to $193.40 despite the FDA extending its review of Leqembi Iqlik by three months to August 24, 2026. The company is also advancing its pipeline through the acquisition of Apellis Pharmaceuticals for $5.6 billion and benefiting from FDA approval of a new high-dose regimen for Spinraza. The stock has gained 63.29% over the past year with positive technical indicators.

The complement inhibitors market is projected to experience strong growth through 2036, driven by rising prevalence of complement-mediated diseases, increased R&D efforts, and approval of new therapeutic agents. The US represents the largest market, with IgAN showing approximately 135,000 diagnosed prevalent cases. Key emerging therapies from major pharmaceutical companies are expected to expand treatment options across multiple indications including PNH, aHUS, CIDP, and IgAN.

Biogen has entered into an agreement with Alloy Therapeutics to accelerate the development of antisense therapies for multiple undisclosed indications. Alloy's AntiClastic ASO platform aims to improve the effectiveness of antisense therapeutics by targeting disease pathways at the RNA level. This partnership follows Alloy's January 2025 collaboration with Sanofi and Biogen's recent acquisition of Apellis Pharmaceuticals for $5.6 billion.

Major M&A activity dominates the market with McCormick merging with Unilever's Foods business in a $29.1 billion deal, Sysco acquiring Jetro Restaurant Depot for $29 billion, and Eli Lilly acquiring Centessa Pharmaceuticals for $7.8 billion. Meanwhile, QVC faces financial distress and is considering Chapter 11 bankruptcy, while several other companies including IO Biotech and Lipella Pharmaceuticals have filed for bankruptcy.

Biogen has agreed to acquire Apellis Pharmaceuticals for $41 per share in cash, valuing the deal at approximately $5.6 billion. The acquisition includes two FDA-approved therapies (Empaveli and Syfovre) with combined 2025 net sales of $689 million and expected mid-to-high teens growth through 2028. Apellis shares surged 136% to $40.36, while Biogen shares declined 4.60% to $178.94.

RTW Investments established a new $193 million position in Apellis Pharmaceuticals by acquiring 7.67 million shares in Q4 2025. Despite a 29% stock decline over the past year, the investment signals confidence in the company's commercial-stage biotech portfolio, which generated $689 million in product revenue driven by its flagship therapy. The position represents a calculated pivot toward more durable revenue streams within a portfolio focused on high-growth biotech names.

Apellis Pharmaceuticals announced its participation in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. The company, a global biopharmaceutical leader in complement science, has two C3-targeting medicines approved for four serious diseases, including the first therapy for geographic atrophy and treatments for rare kidney diseases.

S&P Dow Jones Indices announced index changes effective January 30 and February 2, 2026. TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT will be promoted to the S&P MidCap 400, while Amneal Pharmaceuticals, Apellis Pharmaceuticals, and LegalZoom.com will join the S&P SmallCap 600. These changes follow several pending M&A transactions and corporate actions.

Markets traded cautiously on Tuesday despite benign inflation data (CPI at 2.7% YoY, core CPI at 2.6%) that supported Fed rate cut expectations. Silver surged 4.5% to $89/oz amid supply concerns. Major indices remained flat with the S&P 500 near record highs. Earnings results were mixed: JPMorgan fell 3% on weak investment banking fees, Delta slid 4% on soft guidance, while Moderna rallied 14% on bullish forecasts. Intel and AMD gained on analyst upgrades. Energy stocks outperformed as crude rose 2.7% to $61/barrel.

Apellis Pharmaceuticals reported preliminary full-year 2025 U.S. net product revenues of $689 million, driven by strong performance from SYFOVRE (geographic atrophy treatment) at $587 million and EMPAVELI (kidney disease treatment) at $102 million. SYFOVRE achieved 60% market share with 17% year-over-year injection growth, while EMPAVELI reached over 5% market penetration in its target indications within five months of launch. The company maintains approximately $466 million in cash and expects to reach profitability through product revenues.